netically defined as well as various molecularly de fined subgroups of diffuse largeBcell lymphoma, the 5year overall survival rates after CHOP are vastly different, 2,3 and different cell lines of dif fuse largeBcell lymphoma that are exposed to rituximab respond differently. 2 Lenz and colleagues studied pretreatment bi opsy specimens from 181 patients treated only with CHOP or a CHOPlike regimen (the training group) and specimens from 233 patients treated with RCHOP (the validation group). 1 They looked for new survivalassociated expression signatures at the P<0.01 level in the training group, and they found two, which they called germinalcenter Bcell and stromal1. To refine the signatures, the authors reorganized all the genes in them by hi erarchical clustering according to their expression levels. This exercise resulted in five clusters of coordinately expressed genes, which optimized the likelihood that genes within each cluster would be functionally related and have some physiologi cal relevance. When compared with a bivariate (germinalcenter Bcell vs. stromal1) survival model, these five clusters revealed that one of the five signatures was far superior to the others in adding predictive significance to the bivariate model for the RCHOP cohort. The stromal1 sig nature was associated with a good outcome. How ever, the new signature, which was refined into three gene clusters, one of which the authors call the stromal2 signature, was found to be highly associated with a poor outcome.
In a trivariate model, Lenz and colleagues found strong associations with overall and 3year progressionfree survival in the RCHOP cohort. They used the model to generate a survivalpre dictor score. Model scores were used to divide the T h e ne w e ngl a nd jou r na l o f m e dic i ne n engl j med 359;22 www.nejm.org november 27, 2008 RCHOP cohort into quartile groups, with 3year survival rates ranging from 89% in the best sur vival quartile to 48% in the worst survival quartile and 3year progressionfree survival rates of 84% in the top quartile to 33% in the bottom quartile. Most importantly, the authors showed that the geneexpression model and the International Prog nostic Index enhance each other and are in fact, adjunctive tools.
Lenz and colleagues were able to sort the ma lignant component from the nonmalignant tumor stroma using the CD19 status of the cells. In this manner, they proved that the stromal1 and stro mal2 geneexpression signatures originated from the stromal component. This is an important dif ferentiation, because the converse finding -that the malignant lymphoma cells were producing mesenchymal and extracellularmatrix markerswould give a (surprising) clue to the pathogenesis of diffuse largeBcell lymphoma.
That the tumor stroma could affect a neoplasm is not a new concept; it perhaps dates to more than two decades ago. 4 Over the past 8 years, moreover, multiple independent investigations have uncovered genomic and epigenomic altera tions in a broad range of solidtumor stromal cells in breast, colon, and head and neck carcinomas, and even in the stroma of inflammatory bowel disease. [5] [6] [7] [8] [9] [10] It is also obvious that the cells that compose tumor stroma are themselves heterogeneous. For example, when researchers examined CD10+ breasttumor stromal cells, which consist of myo fibroblasts and rare fibroblastlike cells, only epigenetic, but not genetic, alterations were de tected. 10 However, when CD10− tumor stromal fi broblasts were selected, genomic alterations were evident.
Like diffuse largeBcell lymphoma, stromal al terations in breast and head and neck cancers are associated with clinical outcome. In breast cancer, for example, somatic mutations in the tumorsup pressor gene TP53 in the stroma, but not in the neoplastic epithelium, have been found to be as sociated with regional nodal metastases. 8 In the absence of TP53 mutations in the stroma, loss of heterozygosity at five particular genomic markers, three of which harbor p53 downstream molecules or targets, in the stroma was similarly associated with nodal metastases. Indeed, although TP53 mu tations in tumor stromal fibroblasts accelerate tumorigenesis, they also appear to sensitize tu mors against doxorubicin and cisplatin. 11 In diffuse largeBcell lymphoma, the stromal1 signature, which was associated with a favorable outcome, contains genes encoding components of the extracellular matrix and those of the mono cytic lineage found in T cells and natural killer cells. 1 In contrast, the stromal2 signature, which was associated with a poor outcome, contains genes encoding molecules related to angiogenesis. The association of this signature with a poor prog nosis thus makes sense. One wonders whether an antiangiogenic agent should be added to the treat ment of patients with a lymphoma containing the stromal2 signature. The goal of this kind of research is to integrate germline, or host genomic and epigenomic infor mation, with corresponding information from the cancer to predict outcome and assess risks in se lecting the best therapy with the highest durable response rate and the lowest toxicity (Fig. 1) . With the recognition of the importance of the tumor stroma in tumor invasion, disease progression, and clinical outcome, somatic profiling of the neoplasia must now take into account the tumor microenvironment (Fig. 1) . The challenge in all these integrative endeavors is that genetic data are only as good as the documentation and an notation of the clinical phenotype and outcome. 12
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The Genetics of Speech and Language Impairments
Karin Stromswold, M.D., Ph.D.
Without instruction, most children master the complexities of spoken language by the age of 6 or 7 years. About 5% of apparently healthy children, however, struggle to acquire basic competence in one or more aspects of spoken language and are classified as having specific language impairment. Genetic factors have an important role in many such cases. 1,2 Children with specific language impairment are four times as likely to have a family history of the disorder as are children who do not have such an impairment, 3 and the con cordance rate for the disorder is almost twice as great for monozygotic twins as for dizygotic twins. 4 More than 10 susceptibility loci have been identified. More often than not, loci that are robustly linked to specific language impair ment in one study show no linkage in other studies, and all these loci have been linked to other neurodevelopmental disorders. 5 Are these reported associations real? If so, which genes underlie these linkages, and what is their mecha nistic effect? Perhaps one reason that linkage studies have implicated different loci for specific language impairment is that each group of investigators has used different case definitions. Since the subjects are selected in different ways and differ ent measures are used to define language im pairment, the discovery of different loci would not be unexpected. Studies of relatively homoge neous groups of children with specific language impairment, whose disorders would appear to have a common cause, would seem to be more likely to yield a robust genetic result. Causes that have been proposed for receptive specific lan guage impairment include deficits in shortterm auditory memory, auditory sequencing, and rapid auditory processing.
